| Ytd | -34.53% | |
| 1y | -69.52% |
| Open | 1.47 | Prev Close | 1.53 | Low | 1.43 | High | 1.48 | Mkt Cap | 5.33M |
| Vol | 4.40K | Avg Vol | 24.10K | EPS | -1.10 | P/E | N/A | Forward P/E | -1.28 |
| Beta | 0.99 | Short Ratio | 0.75 | Inst. Own | 7.16% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 1.54 | 200-d Avg | 1.78 | 1yr Est | 10.00 |
PULM News
Advancing PTC-2105 Toward the ClinicEos is in the preclinical stage of development of PTC-2105 and i
Eos SENOLYTIX, Inc. ("Eos" or the "Company"), a biotechnology company developing fir
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.29) per share. This is a 30.95 percent incr
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday&
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.32) per share. This is a 36 percent increas
Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix") and Eos SENOLYTIX, Inc. ("Eos"), a biot
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.25) per share. This is a 54.55 percent incr
As part of the proposed merger, Pulmatrix currently intends to divest its assets including its propr
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.24) per share. This is a 66.2 percent incre
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.42) per share. This is a 73.58 percent incr
Pulmatrix Currently Seeking Divestment of Clinical Assets and Proprietary iSPERSE™ TechnologyiSPERSE
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.50) per share. This is a 317.39 percent dec
Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with th
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.71) per share. This is a 31.07 percent incr
Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.57) per share which beat the analyst consen
Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unm
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.03) per share which beat the analyst consen
On Wednesday, 311 stocks hit new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.
Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inh
Friday's session saw 225 companies set new 52-week lows.
On Wednesday, 59 companies achieved new lows for the year.
On Tuesday, 99 stocks hit new 52-week lows.
Results demonstrate a low likelihood of clinically meaningful drug-drug interactions when PUR1900 is
HC Wainwright & Co. analyst Andrew Fein reiterates Pulmatrix (NASDAQ:PULM) with a Buy and mai
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.04) per share. This is a 23.53 percent incr
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a clinical-stage bioph
On Monday, 120 stocks hit new 52-week lows.
HC Wainwright & Co. analyst Andrew Fein reiterates Pulmatrix (NASDAQ:PULM) with a Buy and mai
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.22) per share. This is a 19.21 percent incr
On Thursday, 185 companies achieved new lows for the year.
PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topl
On Monday, 89 stocks made new 52-week lows.
On Wednesday, 479 stocks made new 52-week lows.
HC Wainwright & Co. analyst Andrew Fein reiterates Pulmatrix (NASDAQ:PULM) with a Buy and mai
Gainers Inspirato Incorporated (NASDAQ: ISPO) shares surged 50.5% to close at $54.90.
Before 10 a.m. ET Monday, 63 stocks made new 52-week lows.
Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.
Monday morning saw 78 companies set new 52-week lows.
This morning 533 companies reached new 52-week highs.
Stocks Which Set New 52-Week Low Mon., Jan. 28, 2019